The EndoBarrier, a non-surgical therapeutic, has received European CE mark approval for the treatment of type 2 diabetes and obesity.
GI Dynamics chief executive officer Stuart Randle said that the company is pleased to establish this partnership with Elemental Healthcare, a premier medical device distribution organization in the UK.
“Elemental Healthcare’s proven sales track record, and experience in the diabetes and obesity markets and with bringing minimally invasive products to healthcare providers and surgeons, will be invaluable as the EndoBarrier becomes commercially available in select markets later this year,” Randle said.
